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Abstract. Differentiation syndrome (DS) represents a life
acute  promyelocytic  leukemia  (APL)  undergoing  induction  therapy  with  all
(ATRA) or arsenic trioxide (ATO). It affected about 20
definitive diagnostic criteria. Clinically, DS is characterized by weight gain, fever not attributable 
to infection, respiratory distress, cardiac involvement, hypotension, and/or acute renal failure. At 
the  histological  point  of  view,  there  is  an  extensive  interstitial  and  intra
infiltration by maturing myeloid cells, endothelial cell damage, intra
hemorrhage,  and  fibrinous  exsudates.  DS  pathogenesis  is  not  completely  understood,  b
believed that an excessive inflammatory response is the main phenomenon involved, which results 
in increased production of chemokines and expression of adhesion molecules on APL cells. Due to 
the high morbidity and mortality associated with DS, it
the treatment is of utmost importance. Dexamethasone is considered the mainstay of treatment of 
DS, and the recommended dose is 10 mg twice daily by intravenous route until resolution of DS. In 
severe cases (respiratory or acute renal failure) it is recommended the discontinuation of ATRA or 
ATO until recovery.
Introduction. Contemporary  treatment  of  acute 
promyelocytic  leukemia (APL)  consists  of  a 
combination  of  all-trans retinoic  acid  (ATRA)  with 
anthracycline-containing  chemotherapy,  or  arsenic 
trioxide (ATO). These modalities of treatment lead to 
complete  remission  rates  greater  than  90%  and  cure 
rates  of  approximately  80%,  in  contrast  with  results 
; Open Journal System 
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Differentiation syndrome (DS) represents a life-threatening complication in patients with 
acute  promyelocytic  leukemia  (APL)  undergoing  induction  therapy  with  all
(ATRA) or arsenic trioxide (ATO). It affected about 20-25% of all patients and so far there are no 
definitive diagnostic criteria. Clinically, DS is characterized by weight gain, fever not attributable 
to infection, respiratory distress, cardiac involvement, hypotension, and/or acute renal failure. At 
view,  there  is  an  extensive  interstitial  and  intra
infiltration by maturing myeloid cells, endothelial cell damage, intra-alveolar edema, inter
hemorrhage,  and  fibrinous  exsudates.  DS  pathogenesis  is  not  completely  understood,  b
believed that an excessive inflammatory response is the main phenomenon involved, which results 
in increased production of chemokines and expression of adhesion molecules on APL cells. Due to 
the high morbidity and mortality associated with DS, its recognition and the prompt initiation of 
the treatment is of utmost importance. Dexamethasone is considered the mainstay of treatment of 
DS, and the recommended dose is 10 mg twice daily by intravenous route until resolution of DS. In 
ratory or acute renal failure) it is recommended the discontinuation of ATRA or 
Contemporary  treatment  of  acute 
(APL)  consists  of  a 
retinoic  acid  (ATRA)  with 
containing  chemotherapy,  or  arsenic 
trioxide (ATO). These modalities of treatment lead to 
complete  remission  rates  greater  than  90%  and  cure 
rates  of  approximately  80%,  in  contrast  with  results 
reported  before  introduction  of  ATRA,  in  which 
disease  free  survival  after  3  years  were  inferior  to 
20%.
1 The introduction of ATRA, which belongs to a 
class  of  chemical  compounds  related  to  vitamin  A 
known  as  retinoids,  to  treat  APL  in  the  1980s 
revolutionized the concept of treatment of cancer, of 
which, besides the aim to destroy by chemotherapy the 
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threatening complication in patients with 
acute  promyelocytic  leukemia  (APL)  undergoing  induction  therapy  with  all-trans  retinoic  acid 
s and so far there are no 
definitive diagnostic criteria. Clinically, DS is characterized by weight gain, fever not attributable 
to infection, respiratory distress, cardiac involvement, hypotension, and/or acute renal failure. At 
view,  there  is  an  extensive  interstitial  and  intra-alveolar  pulmonary 
alveolar edema, inter-alveolar 
hemorrhage,  and  fibrinous  exsudates.  DS  pathogenesis  is  not  completely  understood,  but  it  is 
believed that an excessive inflammatory response is the main phenomenon involved, which results 
in increased production of chemokines and expression of adhesion molecules on APL cells. Due to 
s recognition and the prompt initiation of 
the treatment is of utmost importance. Dexamethasone is considered the mainstay of treatment of 
DS, and the recommended dose is 10 mg twice daily by intravenous route until resolution of DS. In 
ratory or acute renal failure) it is recommended the discontinuation of ATRA or 
reported  before  introduction  of  ATRA,  in  which 
urvival  after  3  years  were  inferior  to 
The introduction of ATRA, which belongs to a 
class  of  chemical  compounds  related  to  vitamin  A 
known  as  retinoids,  to  treat  APL  in  the  1980s 
revolutionized the concept of treatment of cancer, of 
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pathologic  cells, there  is  the  objective  to  enforce  its 
maturation.
2 This  latter  process  culminates  with  cell 
death. ATRA, when administered in pharmacological 
doses, triggers APL cells to differentiate into mature 
granulocytes. The molecular process is not fully known 
but  the  main  aspect  involves  the  degradation  of  the 
complex  PML-RARα,  a  phenomenon  that  unleashes 
the mechanisms required for terminal maturation. 
Besides  ATRA,  arsenic  trioxide  (ATO)  is  an 
important agent that is being used for APL treatment 
since the early 1990s. ATO, or white arsenic, is one of 
the three forms in which arsenic exists.
3 ATO is one of 
the oldest drugs known to man.
4 Despite its reputation 
of  being  a  poison  and  carcinogenic  agent,  ATO  is 
usually well tolerated. This drug degrades PML-RARα 
by targeting its PML moiety (it also degrades normal 
PML).  ATO  provokes  apoptosis  when  used  at  high 
concentration (1-2 x 10
-6 M), or partial maturation of 
APL cells when used at low concentration (0.25-0.5 x 
10
-6 M) and for a longer period of time. Through these 
actions it improves the clinical outcome of refractory, 
relapsed or newly diagnosed APL.
5,6 Both ATRA and 
ATO,  alone  or  in  combination,  can  trigger 
differentiation  syndrome  (DS),  a  relatively  common 
complication  of  APL  treatment  previously  named 
retinoic acid syndrome.
7
Clinically, DS is characterized by weight gain, fever 
not  attributable  to  infection,  respiratory  distress, 
cardiac  involvement,  hypotension,  and  acute  renal 
failure.
7 DS is potentially fatal and its recognition and 
treatment  is  of  utmost  importance.  Histological 
analysis of patients who died of DS revealed extensive 
interstitial and intra-alveolar pulmonary infiltration by 
maturing myeloid cells, endothelial cell damage intra-
alveolar  edema,  inter-alveolar  hemorrhage,  and 
fibrinous exsudates.
7,8
Regarding DS incidence, most studies reported that 
approximately  one  fourth  of  APL  patients  receiving 
ATRA  as  induction  therapy,
9 but  depending  on  the 
criteria  employed;  this  incidence  was  lower.  For 
instance,  Mandelli et  al,  from GIMEMA,  considered 
DS when at least five symptoms were present, and as a 
result DS incidence was of only 2.5% (6/240).
10
As  mentioned previously, ATO  is  also  associated 
with  DS  with  a  similar  frequency.
11 However,  the 
combination of ATRA and ATO was reported to have 
induced  DS  in  only  16%  (13/82)  of  patients.
12 This 
finding is not a surprise, as it was demonstrated that the 
combination  ATRA/ATO  was  associated  with  fewer 
complications than ATRA or ATO alone.
13
Clinical Picture. Table 1 lists the main symptoms of 
DS  and  their  respective  frequency.  De  Botton  et  al 
reported in a large series of patients who developed DS 
revealed  that  respiratory  signs/symptoms  and  fever 
were  the  most  frequent  clinical  presentation  of  DS. 
These  authors  described  413  patients  with  newly 
diagnosed  APL,  64  (15%)  of  which  developed  DS 
(median at day 7), and 9 (14%) patients died of it.
14
Respiratory  involvement  was  reviewed recently.
15 Its 
most common manifestations are pulmonary infiltrate, 
pleural  effusion  and  respiratory  distress.  Cardiac 
involvement  is  more  commonly  characterized  by 
pericardial  effusion,  but  it  can  also  present  as  chest 
pain  typical  of  coronary  obstruction.
16 Rarer  clinical 
presentations such as musculoskeletal symptoms were 
also  reported.
17 There  is  no  pathognomonic  clinical 
sign or laboratory test to diagnose DS. For this reason, 
sometimes  DS  can  be  misdiagnosed  or  confounded 
with  other  concurrent  medical  condition,  such  as 
infection and heart failure. It was suggested to consider 
DS  when  at  least  three  of  the  following  signs  or 
symptoms are present: fever, weight gain, respiratory 
distress,  pulmonary  infiltrates,  pleura  or  pericardial 
effusions, hypotension, and renal failure.
9
Table 1. Clinical picture of DS: approximate frequency of signs 
and symptoms.
Respiratory distress/pulmonary infiltration 80-90%
Fever 80%
Weight gain (> 5 Kg) 50%
Pleural effusion 50%
Renal failure 40%
Pericardial effusion 20%
Cardiac failure 15-20%
Hypotension 10-15%
Among the conditions that clinically resemble DS 
are:  acute  respiratory  distress  syndrome  (ARDS),
18
hyperkeukocytosis/leukostasis  in  AML
19 and 
engraftment  syndrome  after  hematopoietc  stem  cell 
transplantation.
20 In  all  these  conditions,  there  is  an 
organ infiltration, especially the lungs, by granulocytes 
or leukemic cells activated by inflammatory cytokines, 
growth factors or differentiation agents. Curiously, and 
certainly  not  fortuitously,  some  of  them  can  be 
successfully treated with corticosteroids.
Pathogenesis. The  molecular  mechanisms  leading  to 
DS development are not fully known, but it is believed 
that  an  excessive inflammatory response is  the  main 
phenomenon involved. This inflammatory response is 
provoked  by  leukemic  cells  in  the  process  of 
differentiation, which results in increased production of 
chemokines and expression of adhesion molecules on 
APL  cells.  The  inflammation  would  result  in  organ 
infiltration  by  blast  cells,  especially  the  lungs, 
capillary-leak  syndrome  and  organ  failure.  The Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
mechanism must be similar to what occur with normal 
granulocytes  recruited  to  sites  with  inflammation,  in 
which  the  circulating  leukocytes  are  captured by the 
endothelial  cells  (EC)  on  which  occurs  the  process 
called rolling (mediated by selectins), followed by their 
firm  attachment  to  EC  (mediated  by  integrins),  and 
finally,  their  transendothelial  migration  into  the 
tissue.
21 Leukocyte transmigration requires secretion of 
proteases  (metalloproteases  and  neutrophil  elastase) 
that disrupts the endothelial barrier. As a consequence 
there is extravasation of fluids into alveolar space.
22,23
A large array of chemokines  has their production 
greatly  increased  by  treatment  of  APL  cells  with 
ATRA.
24,25 The  migration  of  blast  cells  to  lungs  is 
triggered by increased specific chemokines production 
by alveolar epithelial cells. APL cells are the attracted 
to  lungs  where  they  transmigrate  into  tissue  and 
alveolar space. APL cells also contribute to chemokine 
production,  which  increase  further  blast  recruitment. 
Administration  of  corticosteroids  suppresses 
chemokine  production  by  alveolar  cells  and  then 
abrogates  lung  infiltration.  Besides  corticosteroids, 
neutralizing  antibodies  was  able  to  reduce  in  vitro 
transmigration  of  leukemic  cells  (NB4)  towards 
alveolar epithelial cells (A549).
26,27
In  addition  to  chemokine  increased  production,  it 
was  demonstrated  by  our  group  and  others  that 
treatment with ATRA up-regulated the expression of 
adhesion molecules on blast cells and on endothelial 
cells, and that dexamethasone counteracted the effects 
of ATRA.
28-30 Our group has demonstrated that NB4 
cells  (an  APL  cell  lineage)  and  primary  APL  cells 
treated with ATRA enhanced their expression of CD54 
and  CD18.  Moreover,  mice  injected  with  APL  cells 
previously exposed to ATRA had the lungs infiltrated 
by blasts, demonstrated by increased myeloperoxidase 
(MPO)  activity.  The  infiltration  however  could  be 
blocked by dexamethasone and neutralizing antibodies 
against  adhesion  molecules  CD54  and  CD18. 
Furthermore,  knockout  mice  for  CD54  had  not
increased  MPO  activity  in  lungs  after  injection  of 
treated  APL  cells.  These  findings  demonstrated  the 
main  role  certain  adhesion  molecules  have  in  DS 
development  and  unveil  part  of  the  mechanisms  of 
action  of  corticosteroids  in  treatment  of  this 
syndrome.
30
Risk  Factors.  Risk  factors  for  developing  DS  are 
controversial. Vahdat et al have shown that peripheral 
blood  leukocyte  count  peak  at  the  onset  of  DS 
symptoms.
31 In agreement of this finding, Tallman and 
colleagues reported that in 44 of 167 (26%) patients 
with  APL  receiving  ATRA,  the  median  white  blood 
cell  (WBC)  count  at  diagnosis  was  1,450/µL,  and 
31,000/µL  at  the  time  the  syndrome  was  diagnosed. 
However,  neither  the  initial  leukocyte  count  nor  the 
rate of rise in leukocyte counts on days preceding DS 
correlated  with  its  incidence.  The  European  trial 
showed  that  patients  with  WBC  >  5  x  10
9/L  at 
presentation  and  DS  tended  to  require  mechanical 
ventilation  more  frequently  than  patients  with  lower 
WBC.
14
Regarding  the  expression  of  myeloid  associated 
markers,  in  the  study  of  Vahdat  et  al.  the  basal 
expression of CD13 (amino-peptidase  N) was highly 
associated  with  both  development  of  DS  as  well  as 
with  elevated  leukocyte  count.  However,  others  and 
our group did not find correlation between basal WBC 
count or immune-phenotype characteristics (expression 
of CD33, CD13 and CD117) with incidence of DS ().
32
Recently, Montesinos et al reported the outcome of 
739 APL patients treated with  ATRA and idarubicin 
and  found  that  variables  predictive  of  severe  DS 
included WBC > 5 x 10
9/L, abnormal serum creatinine 
levels, FTL3-ITD mutation, the microgranular subtype, 
the  short  PML-RARA isoform,  and  male  sex.
33
However, in a multivariate analysis, only WBC counts 
and serum creatinine levels were significant. Moreover, 
with  respect  to  APL  morphological  subtype,  the 
microgranular variant (M3V) was found by others to 
protect  against  DS  by  the  US  Intergroup  study.
8
However, recently, Tallman and colleagues, in a large 
joint study of the North American Intergroup and the 
PETHEMA Group, found that the incidence of DS was 
26%  in  M3V  and  25%  for  the  classical  APL  (P= 
0.66).
34
Another factor that seems to influence the incidence 
of DS is the timing of initiation of chemotherapy. De 
Botton  et  al  have  shown  that  early  onset  of 
chemotherapy can reduce the incidence of DS in newly 
diagnosed APL with low WBC count at presentation (< 
5  x  10
9/L). The  incidence  of DS  in  the  ATRA with 
concurrent  chemotherapy  arm  was  lower  than  in  the 
arm  in  which  chemotherapy  was  not  started 
concurrently (9.2% and 18% respectively, P= 0.035).
35
Dore  et  al  reported  an  association  between 
development of DS and the AA genotype at Codon 469 
of ICAM-1, which suggests that susceptibility to DS in 
APL patients may be influenced by genetic variation in 
adhesion  molecule  loci.
36 Finally,  it  was  recently 
demonstrated  that  high  body  mass  index  is  an 
independent predictor of DS.
37
Management and Outcome. As DS can have a subtle 
clinical picture at presentation but progress rapidly, it is 
of utmost importance to be aware of this complication
and initiate therapy as soon as it was suspected. Initial 
measures  involves  ventilatory  and  blood  pressure
support. Dexamethasone is considered the mainstay of 
treatment of DS, and should be administered at the firstMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Measures at suspicion of DS
Chest x-ray, renal function (creatinine and urea), hepatic function (amino transferases and bilirubin), blood cell counts, coagulation tests, 
oxygen saturation
Weight monitoring
Ventilatory support/O2 supplementation
Blood pressure maintenance measures
Fluid restriction (renal failure)
Steroid administration at firs suspicion: dexamethasone 10 mg twice daily until clinical resolution, then tapered dose for a few days
Suspend ATRA or ATO in severe cases, which can be restarted after clinical improvement. If DS recurs after restart, ATRA must be 
definitively discontinued during induction.
sign  or  symptom  of  this  syndrome.  The  dose 
recommended  is  10  mg  twice  daily  by  intravenous 
route until resolution of DS, after which the dose can 
be  progressively  reduced  in  the  next  few  days  or 
weeks. There is no need to discontinue ATRA if DS is 
not  severe.  However,  in  severe  cases  (respiratory  or 
acute renal failure) it seems reasonable to discontinue 
the  drug  until  clinical  recovery,  when  ATRA  could 
then be restarted (Table 2). In the study by Tallman et 
al.  ATRA was discontinued in 36 of the 44 patients 
(82%) that developed DS and resumed in 19 of the 36 
patients (53%). However, DS recurred in 3 (16%) of 
those 19 patients.
8
Prophylactic  administration  of  steroids  is 
controversial.  There  is  no  evidence  of  its  benefit  in 
reducing DS incidence or severity (Sanz et al, 2009). 
For this reason, this approach cannot be recommended 
at moment, despite the report that the prophylactic use 
of corticosteroids from the start of ATRA reduced the 
incidence of severe DS, but not its mortality.
33
Some  patients  have  DS  that  are  refractory  to 
corticosteroids.  There  are  yet  no  widely  accepted 
alternative  to  it.  It  seems  reasonable  to  employ  in 
future  agents  that  block  migration,  adhesion  or 
transmigration  of  APL  cells.  A  few  years  ago, 
Kawasaki  and  colleagues  administered  sivelestat,  a 
small  molecule  that  inhibits  neutrophil  elastase,  and 
that has been shown to be effective in animal models of 
ARDS/ALI, reported its successful use in two patients 
with DS.
38
The frequency of death due to DS varied from 7.8% 
to 33% in clinical trials.
7,39 In the study by De La Serna 
et al DS was responsible for approximately one fifth of 
induction deaths, which occurred at a median of 17
1-26
days  of  starting  induction.
40 Taken  together  these 
results  suggest  that  there  was  a  decrease  in  DS 
mortality  in  recent  years,  probably  due  to  a  more 
prompt  recognition  of  its  symptoms  and  signals  and 
early introduction of therapeutic measures. 
Conclusions. DS is an unpredictable complication of 
treatment  of  APL  with  ATRA  or  ATO,  and  occurs 
usually  after  a  few  days  or  weeks  of  initiation  of 
induction  therapy.  It  is  extremely  uncommon  during 
maintenance treatment. There are no laboratory tests or 
clinical  exams  specific  for  DS.  Considered  alone, 
demonstration  of  diffuse  opacity  of  lungs  on  Rx 
suggestive  of  edema  is  perhaps  the  most  suggestive 
exam for DS.
Treatment  consists  of  ventilation  support  and 
administration  of  steroids  by  intravenous  route  for  a 
few days or weeks after clinical resolution. In severe 
cases  (respiratory  or  acute  renal  failure)  it  seems 
reasonable  to  discontinue  ATRA  until  clinical 
recovery, when it could then be restarted. Concurrent 
chemotherapy can be useful to  reduce incidence and 
severity of DS, despite its potential dangerous effect on 
blood  hemostasis.  Despite  the  fact  that,  in  the  last 
years,  concurrent  chemotherapy  has  reduced  the 
incidence and severity of DS, the most important action
to reduce DS morbidity and mortality remains the early 
recognition  of  its  symptoms,  and  institution  of 
supportive  measures  and  treatment  with 
dexamethasone. 
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